Clinical Trial Update: Omacor in Prevention of Cardiovascular Events in Patients Undergoing Chronic Hemodialysis [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating Omacor for prevention of cardiovascular events in patients undergoing chronic hemodialysis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• Omacor (omega-3-acid ethyl esters)

Snippet

Sponsor: Pronova BioPharma | Conditions: Kidney Failure, Chronic | Phase 4 | Status: COMPLETED